Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Malvern Completes Acquisition of MicroCal

Published: Friday, July 25, 2014
Last Updated: Friday, July 25, 2014
Bookmark and Share
Company announces purchase of Archimedes product from Affinity Biosensors.

Malvern Instruments Ltd has announced that it has completed the acquisition of MicroCal from GE Healthcare Life Sciences and has also purchased the Archimedes particle characterization system from Affinity Biosensors LLC (Santa Barbara, CA). Both of these developments extend Malvern’s portfolio of analytical solutions for the rapidly advancing biopharmaceutical industry.

The agreement to purchase GE Healthcare Life Sciences’ MicroCal business was announced on 4 June 2014 by Malvern’s parent company Spectris plc, and completion follows regulatory approval of the transaction.

MicroCal microcalorimeters are now part of the Malvern Instruments portfolio and are being sold and supported by Malvern Instruments with immediate effect. Users of MicroCal systems have been notified directly of any changes and full details of the product range are available on the Malvern website at http://bit.ly/MALMicro.

Malvern’s purchase of the Archimedes product from Affinity Biosensors follows two years of highly successful collaborative working between the two companies. In 2012, Malvern entered into an exclusive distribution agreement with Affinity Biosensors to market and sell Affinity Biosensors’ Archimedes particle characterization system in all geographies outside of North America, with a co-marketing agreement for North America itself.

Malvern has now acquired the Archimedes product designs and IP and a license to the underlying MIT patent for the technology for relevant fields of use. With this complete, Archimedes becomes a fully Malvern owned product and continues to be supported by the Malvern teams worldwide.

“I am delighted to be announcing the completion of Malvern’s acquisition of MicroCal from GE Healthcare Life Sciences and our purchase of the Archimedes system from Affinity Biosensors,” said Malvern’s Managing Director Paul Walker. “MicroCal microcalorimeters are an exciting and important new addition to Malvern’s portfolio that will significantly extend our ability to serve customers working in pharmaceutical and biopharmaceutical discovery, development and formulation. I’d like to welcome all our new MicroCal colleagues around the world, and look forward to the rapid and productive integration of our businesses.”

Paul Walker continued: “Affinity Biosensors’ Archimedes system has brought the technique of Resonant Mass Measurement into our range, and its close fit within our biopharmaceutical offering has encouraged us to secure its place and future development within Malvern. As part of our analytical toolkit for the biopharmaceutical industry, Archimedes sits alongside Zetasizer and NanoSight Nanoparticle Tracking Analysis systems, delivering a range of complementary solutions for quantifying early aggregation in bioformulations.”

Microcalorimetry is a tool that is used at almost every stage of the drug discovery, development and formulation process. MicroCal has more than 30 years’ experience in this field, with established ranges of differential scanning calorimeters (DSC) and isothermal titration calorimeters (ITC) all designed to meet the quality and productivity needs of today’s life science laboratories. These systems are an excellent fit with Malvern’s existing portfolio of measurement solutions for the pharmaceutical and biopharmaceutical industries. Their ability to deliver information about drug binding and protein stability is complementary to Malvern’s current products and to those in development.

Archimedes uses the technique of Resonant Mass Measurement to detect and count particles. It determines their mass and size with high resolution and accuracy in small sample volumes. A key area of application is the measurement of protein aggregation in biotherapeutic formulations, which provides critical information needed to speed development and improve drug safety and efficacy.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Malvern Instruments Establishes New Biopharmaceutical Applications Laboratory
Malvern Instruments has established a new biopharmaceutical applications laboratory in the heart of San Diego’s biotechnology cluster.
Friday, July 31, 2015
Educating Industry-Ready Nanotechnology Technicians
Seattle’s Hub for Industry-Driven Nanotechnology Education has identified dynamic light scattering particle sizing as an essential analytical technique, investing in a Zetasizer Nano from Malvern Instruments.
Monday, June 22, 2015
Researchers use Nanoparticle Tracking Analysis to Study Extracellular Vesicles
Scientists are working to find a way deliver a specific microRNA species capable of retarding the growth of tumor cells.
Thursday, May 28, 2015
New Educational Resources from Malvern
Provide a valuable grounding in polymer solution characterization.
Saturday, May 16, 2015
Malvern To Present New Research at ISFRS
Malvern puts the spotlight on cutting edge analytical strategies at ISFRS 2015.
Monday, May 11, 2015
Solving the Problem of Lignin Characterization
Malvern presents proven strategies for successful GPC/SEC analysis.
Friday, May 01, 2015
Malvern to Acquire MicroCal Business from GE
Malvern Instruments has entered into an agreement with GE Healthcare Life Sciences to acquire the company’s MicroCal™ microcalorimetry business.
Wednesday, June 04, 2014
Malvern Awarded £3M UK Government Funding
Company secured £3M support from the UK Government’s Regional Growth Fund (RGF) that will lead to the creation of 47 new jobs in the UK over the next five years.
Sunday, June 01, 2014
Regional Growth Fund Success Sees Malvern Instruments Stepping up UK Recruitment
£3 million support from the UK Government’s Regional Growth Fund (RGF) will lead to the creation of 47 new jobs in the UK over the next five years.
Tuesday, May 20, 2014
Scientific News
NIH Study Finds Calorie Restriction Lowers Some Risk Factors for Age-Related Diseases
Two-year trial did not produce expected metabolic changes, but influenced other life span markers.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!